Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma
Status:
Recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well obinutuzumab, ibrutinib, and venetoclax work in treating
patients with previously untreated stage II-IV follicular lymphoma. Immunotherapy with
obinutuzumab may induce changes in body's immune system and may interfere with the ability of
tumor cells to grow and spread. Ibrutinib and venetoclax may stop the growth of tumor cells
by blocking some of the enzymes needed for cell growth. Giving obinutuzumab, ibrutinib, and
venetoclax together may work better in treating follicular lymphoma compared to each drug
alone.
Phase:
Phase 2
Details
Lead Sponsor:
Joseph Tuscano
Collaborators:
Genentech, Inc. National Cancer Institute (NCI) Pharmacyclics LLC.